NCAM1 and myelodysplastic syndrome: Moreover, CD56 aberrant expression in myeloblasts was seen in only 5% cases of MDS, thereby reducing its utility was considered as a potential marker for MDS, particularly in evaluating dysplasia in granulocytes and blasts.